Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MiRNA expression in cerebrospinal fluid with moyamoya disease

ABSTRACT: miRNA expression in cerebrospinal fluid with moyamoya disease

PROVIDER: PRJNA532836 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

miRNA expression in cerebrospinal fluid with moyamoya disease

Project description:We performed microarray analysis to determine the expression profiles of miRNAs in cerebrospinal fluid with moyamoya disease

2020-04-03 | GSE129792 | GEO

MiRNA expression in cerebrospinal fluid of angiogenesis or non-angiogenesis after Encephalo-myo-synangiosis in patients with moyamoya disease

Project description:At present, the treatment for moyamoya disease (MMD) primarily consists of combined direct and indirect bypass surgery. Nevertheless, more than half of indirect bypass surgeries fail to develop good collaterals from the dura and temporal muscle. This study aimed to investigate whether microRNAs (miRNAs) in cerebrospinal fluid (CSF) could serve as biomarkers for the prediction of postoperative collateral formation.

2021-07-14 | GSE168469 | GEO

MiRNA sequencing for CSF-derived EVs microRNAs in patients with moyamoya disease and arteriosclerotic cerebral ischemia

Project description:We aimed to clarify what specific changes occur in the expression level of extracellular vesicles (EVs) -derived microRNAs (miRNAs) in intracranial cerebrospinal fluid (CSF) in moyamoya disease. Patients with arteriosclerotic cerebral ischemia were used as controls to eliminate the effects of cerebral ischemia. Comprehensive expression analysis of miRNAs extracted from EVs by the next-generation sequencer was performed.

2022-04-22 | GSE193012 | GEO

MiRNA expression in cerebrospinal fluid of angiogenesis or non-angiogenesis after Encephalo-myo-synangiosis in patients with moyamoya disease

Project description:MiRNA expression in cerebrospinal fluid of angiogenesis or non-angiogenesis after Encephalo-myo-synangiosis in patients with moyamoya disease

| PRJNA707504 | ENA

miRNA Expression from Cerebrospinal Fluid (CSF) from Prodromal Huntington Disease Patients

Project description:miRNA Expression from Cerebrospinal Fluid (CSF) from Prodromal Huntington Disease Patients

| PRJNA631401 | ENA

Cerebrospinal fluid

Project description:Cerebrospinal fluid Genome sequencing

| PRJNA856347 | ENA

Human cerebrospinal fluid autoantibody lipid microarray profiling

Project description:This SuperSeries is composed of the following subset Series: GSE37664: Human cerebrospinal fluid autoantibody lipid microarray profiling (Fig. 1A) GSE37670: Human cerebrospinal fluid autoantibody lipid microarray profiling (Fig. 2A) GSE37826: Human cerebrospinal fluid autoantibody lipid microarray profiling (Fig. 2C) Refer to individual Series

2012-05-08 | E-GEOD-37830 | biostudies-arrayexpress

Transcriptional profiling of cerebrospinal fluid cells of multiple sclerosis patients

Project description:RNA was isolated from fresh cerebrospinal fluid samples of multiple sclerosis and control patients and analyzed by hybridization of HG U133 plus 2.0 arrays in order to investigate disease mechanisms of multiple sclerosis and to identify transcriptional biomarker

2014-06-01 | E-MTAB-2374 | biostudies-arrayexpress

Determination of the serum miRNA expression profile in human moyamoya disease (MMD)

Project description:Moyamoya disease (MMD) is a cerebrovascular disease characterized by progressive stenosis of the intracranial internal carotid arteries and their proximal branches. However, the etiology of this rare disease remains widely unknown. Serum microRNA (miRNA) profiles have been screened to identify novel biomarkers for disease diagnosis and prognosis. Here, we identified important serum miRNAs that might play important roles in contributing to MMD pathogenesis through microarray analysis. 10 MMD patients and 10 controls were consecutively recruited at Shanghai Changhai Hospital. Five-ml venous blood was collected from each participant and separated into serum and cellular fractions. We pooled serum samples from 10 MMD patients and 10 controls. Agilent Human 8 x 60K miRNA Array was performed on the two pooled samples.

2013-04-04 | E-GEOD-45737 | biostudies-arrayexpress

Determination of the serum miRNA expression profile in human moyamoya disease (MMD)

2013-04-04 | GSE45737 | GEO